On the diabetes-to-stomach side of the model, chronic hyperglycemia is presented as the initiating pressure. Excess glucose overloads mitochondrial electron transport, increases reactive oxygen species and activates pathways including NADPH oxidase. In diabetic animals, the review reports higher concentrations of lipid peroxidation products such as MDA and 4-HNE in gastric mucosa, reduced antioxidant enzyme activity, activation of the NF-κB inflammatory axis, an unfavorable balance between the anti-apoptotic protein Bcl-2 and pro-apoptotic Bax, and activation of caspase-9 and caspase-3. The resulting epithelial apoptosis, impaired cell proliferation and thinned lamina propria provide a plausible route from hyperglycemia to gland loss and mucosal atrophy. This evidence comes primarily from experimental models and does not establish the same sequence in human diabetes.

Advanced glycation end products, or AGEs, add another proposed route. High glucose promotes non-enzymatic glycation of long-lived matrix proteins including collagen and laminin, altering their cross-linking and physical properties. When AGEs engage the receptor for AGEs, or RAGE, they can activate NF-κB and MAPK signaling, stimulate NADPH oxidase and promote further reactive oxygen species. Animal studies summarized in the review associate elevated AGEs with structural disorders, while experimental findings connect RAGE signaling to impaired fibroblast function, reduced collagen synthesis and delayed healing. AGE cross-linking may also make the mucosa less compliant and more vulnerable to acid, bile and Helicobacter pylori. The authors describe this as a positive feedback loop in which oxidative stress and glycation reinforce one another, but they acknowledge that direct longitudinal evidence in patients remains limited.

Diabetes may also compromise the stomach’s blood supply and its capacity to repair. Diabetic microangiopathy affects the small vessels beneath the gastric mucosa, producing endothelial swelling, luminal narrowing, reduced perfusion density and chronic ischemia. The review cites measurements showing lower mucosal blood flow in people with diabetes than in healthy controls and patients with chronic superficial gastritis. Reduced nitric oxide bioavailability, increased asymmetric dimethylarginine and elevated von Willebrand factor can further disturb microcirculation and microthrombosis. Prolonged hypoxia stabilizes HIF-1α, which may initially support adaptation but, when chronically imbalanced, can sustain inflammatory signaling, reduce tight-junction proteins and hinder epithelial regeneration. Deficits in prostaglandin E2, epidermal growth factor and TGF-β signaling are also described as weakening mucus and bicarbonate protection and slowing the reconstruction of damaged epithelium.

Neurological complications add a gastric-motility component. Diabetic autonomic neuropathy can reduce vagal stimulation of acid-secreting parietal cells, disturb the balance between gastrin-secreting G cells and somatostatin-secreting D cells, and impair the protective role of ghrelin. Diabetic gastroparesis is characterized in the review by weak antral contractions, increased pyloric resistance and delayed emptying of solid food. Retention and reflux of bile- and enzyme-rich duodenal contents can damage epithelial tight junctions and cell membranes. Loss or dysfunction of interstitial cells of Cajal, the stomach’s electrical pacemaker cells, further disrupts contractions, and experimental work links oxidative stress, microvascular injury, pro-inflammatory macrophages and altered autophagy to their decline. Together, delayed emptying, bile reflux, mucosal injury, cellular loss and worsening motility are proposed to form a self-reinforcing sequence that can progress from chronic inflammation to gland atrophy and intestinal metaplasia.

Helicobacter pylori provides a potential meeting point between hyperglycemia, infection and atrophy. The review describes altered glycosylation of gastric mucins in a high-glucose environment, which may expose structures that improve bacterial adhesion, together with reduced acidity that weakens the stomach’s chemical defense. Diabetes-associated impairment of neutrophil chemotaxis, phagocytosis and intracellular killing may make early clearance less effective, while macrophage responses become more strongly skewed toward inflammation. H. pylori can also induce the immunosuppressive cytokine IL-37 through receptors including TLR2, TLR4 and NOD1. Its virulence factors, notably CagA from cag-positive strains, can amplify NADPH oxidase activity, oxidative damage and NF-κB signaling, potentially accelerating the sequence from gastritis to atrophy and metaplasia. These observations suggest that infection, immune dysfunction and high glucose may cooperate, but they do not show that every patient with diabetes follows this course or that eradication alone prevents atrophy.

In the reverse direction, atrophic gastritis may disturb glucose metabolism through several partially overlapping mechanisms. Loss of parietal cells reduces gastric acid and intrinsic factor, impairing the release and terminal-ileal absorption of vitamin B12 and reducing the conversion of dietary iron to a more soluble form. B12 deficiency can lead to hyperhomocysteinemia, which has been associated with oxidative stress, endothelial injury and insulin resistance. Preclinical evidence also links homocysteine to endoplasmic-reticulum stress, mitochondrial dysfunction and apoptosis in pancreatic beta cells. Iron deficiency may restrict mitochondrial complex IV activity and ATP production in insulin-sensitive tissues, potentially worsening insulin signaling and glucose-stimulated insulin secretion. These pathways are biologically coherent, but the review notes that much of the evidence is preclinical and that trials demonstrating improved glycemic control after correction of atrophic-gastritis-related deficiencies are scarce.

Changes in the gastric endocrine network offer a second potential route. Loss of acid removes negative feedback on antral G cells, producing marked hypergastrinemia, while impaired D-cell function may weaken somatostatin inhibition. Although moderate gastrin elevations can have metabolic or trophic effects under physiological conditions, the review proposes that sustained supraphysiological stimulation of CCK-B receptors on beta cells may desensitize insulin secretion, deplete functional reserves and interfere with beta-cell transcription factors. Atrophic gastritis affecting the gastric body and fundus can also destroy X/A-like cells, the main source of ghrelin, altering meal-related hunger signals and potentially removing ghrelin’s inhibitory influence on basal insulin secretion. Because ghrelin also affects skeletal-muscle mitochondrial function and inflammation, its loss may intersect with diabetic sarcopenia and insulin resistance. These consequences remain mechanistically inferred rather than demonstrated by prospective hormone-intervention trials.

Low gastric acidity can also permit small intestinal bacterial overgrowth, altering microbial metabolites and the gut-liver-pancreas axis. Lipopolysaccharide from Gram-negative bacteria may enter portal circulation, activate TLR4 and inflammatory pathways such as JNK and IKK/NF-κB, and contribute to systemic insulin resistance. Changes in short-chain fatty acids and bile-acid metabolism may affect intestinal barrier integrity and the incretin hormones GLP-1 and GIP. The review reports associations between overgrowth, dysbiosis, irregular glucose regulation and reduced post-meal incretin responses, but notes that microbial and short-chain-fatty-acid responses can be complex and cannot be reduced to a single pathway. A major shared mechanism in the proposed cycle is disruption of the PINK1/Parkin mitophagy pathway: experimental findings associate high glucose and inflammation with reduced Parkin activity, damaged mitochondrial accumulation, impaired autophagic flux and apoptosis in both gastric epithelium and pancreatic beta cells, while leaked mitochondrial DNA can further activate STING and NF-κB signaling.

The review also identifies a shared immune and genetic background. HLA class II haplotypes such as DR3-DQ2 and DR4-DQ8 have been associated with susceptibility to both diseases, while anti-islet, anti-parietal-cell and intrinsic-factor antibodies occur in subsets of patients with diabetes. An imbalance between pro-inflammatory Th17 cells and regulatory T cells is another proposed link, with IL-17A activating NF-κB and STAT3-driven differentiation potentially contributing to injury of both gastric parietal cells and pancreatic beta cells. Yet the authors are explicit that none of the principal connecting nodes has been validated in a large prospective interventional study of comorbid patients. They call for longitudinal cohorts that repeatedly measure glucose control, gastroscopy, mucosal histology and biomarkers; dual-disease animal models and patient-derived gastric organoids; and simultaneous profiling of gastric and metabolic pathways. The review’s proposed antioxidant, hormonal, microecological and autophagy-based interventions are consequently early-stage research directions, not proven treatments for breaking the diabetes–gastritis cycle.

Subject of Research: Proposed bidirectional mechanisms linking diabetes mellitus and atrophic gastritis

Article Title: Diabetes mellitus and atrophic gastritis: progress in the study of interactive pathogenesis

Article References: Zhu, Z., Wang, L., Zhou, T., Che, Y., Shi, Y., Song, J., Zhang, Z., Xu, J., Tian, S., Qu, N., Lu, Y., Hao, Y., Zhang, J., Gao, H., & Lv, H. (2026). Diabetes mellitus and atrophic gastritis: progress in the study of interactive pathogenesis. Frontiers in Endocrinology, 17, Article 1955709. https://doi.org/10.3389/fendo.2026.1955709

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1955709

Keywords: diabetes mellitus, atrophic gastritis, hyperglycemia, gastric mucosa, oxidative stress, gut microbiome, insulin resistance, vitamin B12, gastroparesis, Helicobacter pylori, Diabetes, mellitus

Probiotics have long been proposed as a way to soften these side effects, potentially by attenuating antibiotic-induced disruption of the gut microbiota, reinforcing colonization resistance, and modulating mucosal immune responses. Previous meta-analyses, however, pooled trials that mixed proton pump inhibitors, vonoprazan, and other acid suppressants with different antibiotic backbones, probiotic strains, doses, and durations. That heterogeneity, the review authors argued, obscured what probiotics actually add when the underlying regimen is otherwise fixed.

To answer that narrower question, the team searched eight bibliographic databases and three trial registries from inception through mid-July 2026, with no language restrictions. Eligible studies were randomized controlled trials in adults with confirmed H. pylori infection comparing a vonoprazan-based regimen plus a probiotic against the identical regimen without one, with probiotic administration overlapping the eradication course. The searches identified 506 database records and 19 registry records; after screening, sixteen reports corresponding to nine independent randomized studies met the criteria, encompassing 1,270 participants.

All nine trials were conducted in China, one multicenter and eight single-center, published or completed between 2023 and 2026. Six evaluated vonoprazan-amoxicillin dual therapy, one vonoprazan-based triple therapy, and two bismuth-containing quadruple therapy, with treatment durations of 10 days, 14 days, or, in one atypical case, four weeks. The probiotic interventions were biologically diverse, ranging from Bacillus subtilis plus Enterococcus faecium and Saccharomyces boulardii to compound lactic acid bacteria, Bifidobacterium capsules, Bacillus licheniformis, and a Bifidobacterium tetravaccine.

Eradication was generally confirmed by urea breath testing at least four weeks after treatment. Statistically, the team pooled risk ratios using restricted maximum-likelihood random-effects models with Hartung-Knapp confidence intervals, and reported 95 percent prediction intervals to estimate what a future comparable trial might show. The primary outcome was the proportion of participants experiencing at least one adverse event, treated as a participant-level binary measure rather than a count of episodes.

The reviewers used the Cochrane Risk of Bias 2 tool for outcome-specific bias assessments and GRADE to rate certainty, and excluded studies with ambiguous adverse-event totals or serious allocation concerns from the primary analyses. The tolerability signal was striking. Across five studies involving 611 participants, adjunctive probiotics reduced the risk of experiencing at least one adverse event by roughly 70 percent (risk ratio 0.30, 95 percent confidence interval 0.17 to 0.53; P = 0.004), with zero statistical heterogeneity.

The prediction interval, 0.12 to 0.79, remained entirely below the null, suggesting benefit would be expected in a future similar trial. Translated into absolute terms, the risk fell from 261 to about 79 per 1,000 treated, meaning roughly one additional patient avoids an adverse event for every six given probiotics. Sensitivity analyses kept the estimate between 0.31 and 0.38, and GRADE certainty was rated moderate.

The efficacy picture was far less convincing. Intention-to-treat eradication across seven studies and 910 participants showed a small apparent benefit (risk ratio 1.09, 95 percent confidence interval 1.00 to 1.19), but the prediction interval of 0.92 to 1.30 crossed no effect, and statistical significance vanished in sensitivity analyses that excluded dissertation-based or methodologically atypical studies. Per-protocol eradication showed little or no difference (risk ratio 1.03), and adherence, already high at about 95 percent in control groups, was not clearly improved.

Individual symptoms such as constipation, bloating, and nausea trended in probiotics' favor, but these analyses rested on few events and were graded very-low-certainty. Discontinuation and serious adverse events were too rare to yield interpretable estimates. The authors caution that all included trials were conducted in China, and that regional differences in antimicrobial resistance, prior antibiotic exposure, diet, baseline microbiota, probiotic product quality, and symptom-reporting behavior may limit generalizability to other populations.

Most trials were also open-label, a concern for subjectively reported adverse events, and the data cannot identify an optimal probiotic strain, dose, or timing. The reviewers conclude that probiotics are best framed as supportive care to improve tolerability during vonoprazan-based therapy, not as a means of raising cure rates, and they call for adequately powered, placebo-controlled, multicenter trials with standardized outcome definitions and strain-level reporting to confirm the findings in diverse settings.

Subject of Research: Adjunctive probiotics during vonoprazan-based Helicobacter pylori eradication therapy

Article Title: Adjunctive probiotics may reduce adverse events during vonoprazan-based Helicobacter pylori eradication: a systematic review and meta-analysis

Article References: Lin, C.-J., Ren, P.-Y., Chen, H.-Y., Zheng, M.-Q., Jiang, Y.-X., Li, G., Fu, M., & Guo, Y.-H. (2026). Adjunctive probiotics may reduce adverse events during vonoprazan-based Helicobacter pylori eradication: a systematic review and meta-analysis. Frontiers in Pharmacology, 17, Article 1946885. https://doi.org/10.3389/fphar.2026.1946885

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1946885

Keywords: Helicobacter pylori, vonoprazan, probiotics, meta-analysis, adverse events, eradication therapy, gut microbiota, potassium-competitive acid blocker, tolerability, randomized controlled trials, GRADE certainty, gastroenterology

The researchers enrolled 842 consecutive symptomatic adults referred for upper gastrointestinal endoscopy. They collected sociodemographic, behavioral, clinical and endoscopic information through a standardized questionnaire and compared enzyme-linked immunosorbent assay (ELISA) and rapid urease testing with histopathological examination using hematoxylin and eosin staining. Histology served as the diagnostic gold standard, while logistic regression was used to identify factors independently associated with infection. Epigastric pain was the most common indication for endoscopy, reported in 59.9% of participants. Erosive lesions or ulcerations were the predominant endoscopic findings in 28.4%, and inflammatory lesions were documented in 22.3%.

ELISA showed sensitivity of 99.7%, specificity of 100.0% and diagnostic accuracy of 99.8% against histology, with almost perfect agreement (κ = 0.994). The rapid urease test had sensitivity of 88.3%, specificity of 88.5% and diagnostic accuracy of 88.4%, representing substantial agreement with histology (κ = 0.722). Infection was present in all patients with gastric tumors, 91.2% of those with active duodenal ulcers and 82.1% of those with active gastric ulcers.

Logistic regression identified several demographic, clinical and behavioral factors independently associated with infection. These included younger age, defined in the abstract as 15–32 years (adjusted odds ratio, 2.88); living in households with five members (9.83); blood group O (2.25); vomiting (12.60); investigation for anemia (16.38); and absence of medication use (4.33). These were associations in the study population and do not establish causation.

The results apply to symptomatic patients referred for endoscopy at two tertiary hospitals in Douala, not to the broader population of the city or Cameroon. Because the study was cross-sectional, it cannot determine whether the reported factors preceded infection or changes over time. The supplied evidence is an abstract from an early open-access version of the article, which states that further editorial changes may follow; confidence intervals and other detailed measures of uncertainty were not provided in the abstract.

Subject of Research: Cross-sectional assessment of H. pylori prevalence and diagnostic test performance among symptomatic adults undergoing endoscopy in Douala, Cameroon

Article Title: High prevalence and endoscopic patterns of Helicobacter pylori Infection among symptomatic adults in Douala, Cameroon: sociodemographic and behavioral correlates

Article References: Eyoum, B. B. B., Eloumou, F. S. B., Medi, C. S., Ekwala, J. R. M. N., Ntonga, C. L., Malongue, A., Fotso, C., Fotsing, S., Kamdem, C., Ateba, R. G., Kouitcheu, B. L. M., & Kuiate, J.-R. (2026). High prevalence and endoscopic patterns of Helicobacter pylori Infection among symptomatic adults in Douala, Cameroon: sociodemographic and behavioral correlates. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14451-8

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14451-8

Keywords: Helicobacter pylori, Douala, Cameroon, cross-sectional study, endoscopy, histology, ELISA, rapid urease test, prevalence, endoscopic findings, High, endoscopic

The scale of the colorectal cancer problem gives the result immediate public health weight. Colorectal cancer is the second leading cause of cancer-related death worldwide, and in 2022 nearly two million new cases were diagnosed globally. Because screening, diet and lifestyle interventions only partially explain or prevent this burden, researchers have long searched for additional modifiable risk factors. H. pylori has been an established gastric carcinogen for decades, but its potential role in colorectal cancer has remained one of the more controversial questions in gastroenterology, with individual studies producing conflicting results. The new analysis was designed to settle the question at a scale no single cohort could achieve.

To do so, the research team assembled a remarkably large evidence base: 43 international studies encompassing approximately 48.7 million individuals. Rather than relying on any single dataset, the investigators combined global and regional estimates of H. pylori prevalence with colorectal cancer incidence data drawn from the Global Cancer Observatory (GLOBOCAN) 2022, the authoritative international cancer statistics platform maintained by the World Health Organization’s cancer agency. This risk attribution modelling approach allowed the team to examine how the association varied by diagnostic method used to detect the bacterium, by sex, and across World Health Organization regions, providing a layered picture of where and among whom the infection’s contribution to bowel cancer might be greatest.

The headline result was striking. H. pylori exposure was associated with a 1.59-fold increased risk of colorectal cancer compared with individuals without exposure to the bacterium. From this elevated risk and the widespread prevalence of the infection, the researchers estimated that H. pylori exposure could potentially account for approximately 22 percent of colorectal cancer cases globally. Crucially, the team stress-tested the finding by restricting the analysis to the 14 most methodologically robust studies, those that were population-based or cohort designs, which are less vulnerable to the biases that can distort case-control comparisons. Even in this conservative subset, approximately 12 percent of colorectal cancer cases remained potentially linked to H. pylori exposure, indicating that the association is not an artefact of weaker study designs.

Professor Leung Wai-keung, Li Shu Fan Medical Foundation Professor in Gastroenterology and Chair Professor of Gastrointestinal Medicine in HKUMed’s Department of Medicine, emphasised the practical implications of the discovery. Unlike many inherited cancer risks, he noted, H. pylori infection is both detectable and treatable. He said the study suggests the bacterium may contribute substantially to the global burden of colorectal cancer, and that understanding this relationship could help inform future prevention strategies and identify new opportunities to reduce risk worldwide. In other words, a simple course of antibiotics and a breath or stool test, tools already deployed against gastric cancer, could theoretically shave a meaningful fraction off bowel cancer incidence as well.

The study also looked at what happens when the bacterium is eliminated. Although the evidence remains limited, existing observational studies indicate that people who received eradication treatment experienced a lower risk of colorectal cancer after more than 10 years of follow-up. That delayed protective effect fits with the known biology of colorectal cancer, which typically develops over many years through the accumulation of genetic and epigenetic changes in the cells lining the colon and rectum. Removing a contributing carcinogen would not be expected to reverse existing lesions overnight, but it could slow or prevent the sequence of events that ultimately produces tumours. The authors caution, however, that further prospective and interventional studies are required before eradication can be formally recommended as a bowel cancer prevention measure.

Geography emerged as a major theme in the analysis. The researchers observed that countries with higher H. pylori prevalence tended to carry a greater estimated colorectal cancer burden attributable to the infection. The Western Pacific region, which includes China, Mongolia and Vietnam, recorded the highest estimated proportion of colorectal cancer cases linked to H. pylori exposure, at approximately 25 percent. China alone had the largest absolute number of colorectal cancer cases potentially associated with the bacterium, a consequence of both its substantial infection prevalence and its enormous population. This regional pattern suggests that eradication programmes could deliver their greatest cancer-prevention dividends precisely in areas where healthcare resources are often most stretched.

One of the more counterintuitive findings concerns generational change. The researchers found that later birth cohorts appeared to carry a proportionally higher H. pylori-related colorectal cancer burden, even though the prevalence of the infection has been declining over time. The estimated proportion of colorectal cancer linked to the bacterium rose from 9.5 percent among people born before 1947 to 15 percent among those born between 1963 and 1977. The reasons for this shift are not yet clear, and the team highlights the need for further research into how infection, lifestyle and environmental factors may interact to influence cancer risk across generations. Possibilities include changing dietary patterns, altered gut microbiomes, and differences in age at exposure, all of which could modulate how a chronic gastric infection influences distant intestinal tissue.

The prospect of a dual benefit is what elevates the study from an academic curiosity to a potential turning point in cancer prevention policy. Many countries and regions have already introduced population-based H. pylori screening and eradication programmes with the explicit goal of reducing gastric cancer risk. Professor Leung said the findings suggest these programmes could potentially generate a dual cancer-prevention benefit by reducing the risks of both gastric cancer and colorectal cancer, particularly in areas where H. pylori infection remains highly prevalent and healthcare resources are limited. Because the same screening infrastructure, diagnostic tests and treatment regimens would serve both goals, the marginal cost of extending protection to the bowel could be comparatively low.

Professor Leung added that the team’s goal is to provide evidence that informs public health and research priorities and to guide infection-targeted prevention strategies at both global and regional levels, complementing and extending beyond H. pylori eradication efforts to reduce the risk of multiple cancers. The study was supervised by Professor Leung and Professor Shailja Shah of the University of California San Diego as joint senior authors, with PhD student Yunhao Li of HKUMed’s Department of Medicine as first author. The international collaboration also included Erasmus MC in the Netherlands and Brown University in the United States. If future interventional trials confirm what this modelling study suggests, the humble stomach bacterium that medicine has spent decades fighting could become an even more valuable target, offering a rare opportunity to strike two major cancers with a single, inexpensive intervention.

Subject of Research: Association between Helicobacter pylori exposure and global colorectal cancer risk

Article Title: HKUMed-led international study finds Helicobacter pylori exposure may be associated with more than one in five colorectal cancer cases worldwide

Article References: HKUMed-led international study finds Helicobacter pylori exposure may be associated with more than one in five colorectal cancer cases worldwide. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Helicobacter pylori, colorectal cancer, cancer prevention, epidemiology, GLOBOCAN, gastric cancer, risk attribution modelling, HKUMed, Western Pacific region, eradication programmes, public health, observational study

The clinical picture in the ulcer group was strikingly different from that of the healthy controls. Abdominal pain was reported in 82.6 percent of children with ulcers versus 15.2 percent of healthy children, vomiting in 63.0 percent versus 8.7 percent, and melena — black, tarry stools indicating gastrointestinal bleeding — in 19.6 percent versus zero percent. Laboratory indicators reinforced the divide: H. pylori infection, detected by the 13C-urea breath test, was present in 63.0 percent of the ulcer group versus 8.7 percent of controls, and anemia affected 45.7 percent versus 12.0 percent. A positive fecal occult blood test was found in 38.0 percent of children with ulcers compared with just 3.3 percent of healthy children. Gastroscopy revealed that ulcers predominantly occurred in the duodenal bulb, accounting for 68.5 percent of cases, followed by the gastric antrum at 23.9 percent and compound ulcers affecting both stomach and duodenum at 7.6 percent.

Why does the duodenal bulb emerge as the most vulnerable site? The researchers point to its distinctive anatomy and physiology. The duodenal bulb mucosa lacks the protective mucus layer found elsewhere in the gastrointestinal tract, and its submucosa is richly supplied with blood vessels and nerve endings, making it susceptible to acid erosion. This site sits in the peak area of gastric acid secretion, and gastric antrum motility can directly transport acid toward the duodenal bulb, creating a locally high-acid environment. The gastric antrum, the second most common ulcer location, may be vulnerable because of H. pylori colonization patterns, antral motility, and relatively weak local mucosal defense. The presence of compound ulcers in a subset of children suggests that multi-site involvement can occur, underscoring the need for comprehensive endoscopic examination rather than targeted inspection of a single region.

The mechanism behind abdominal pain in these children is closely tied to ulcer location and inflammatory mediators. The duodenal bulb submucosa contains a rich supply of nerve endings, and once an ulcer forms, it directly stimulates pain-sensing fibers, triggering upper abdominal or periumbilical pain. Mediators such as prostaglandins and histamine released during the inflammatory response around the ulcer enhance nerve sensitivity and lower the pain threshold. Notably, the abdominal pain in the ulcer group was mainly postprandial — occurring after meals — which the researchers attribute to the peak period of gastric acid secretion and increased gastric antrum motility. After eating, acid that is not neutralized by food contacts the ulcer surface directly, exacerbating pain, while increased antral motility may push acid toward the duodenal bulb, aggravating local irritation. In contrast, the low incidence of abdominal pain among healthy children was mostly functional, related to motility abnormalities or visceral hypersensitivity rather than organic lesions.

Vomiting and melena reflect the complication profile of peptic ulcers. The significantly elevated vomiting rate in the ulcer group may be related to pyloric obstruction or delayed gastric emptying: when an ulcer is located near the pylorus, local edema or scar formation can cause mechanical stenosis, producing postprandial vomiting that may contain bile. Vagus nerve excitation caused by the ulcer can also inhibit gastric antrum motility and delay emptying, leading to nausea and vomiting. Melena, a typical manifestation of gastrointestinal bleeding, arises when ulcer erosion damages blood vessels. In children, bleeding often presents as occult blood loss or small amounts of hematemesis, partly because children have thinner blood vessels and bleeding is prone to self-coagulation. However, long-term chronic blood loss can lead to anemia — which explains the markedly higher anemia incidence in the ulcer group. The complete absence of melena in the healthy group further confirms its clinical value as a specific symptom of peptic ulcer.

H. pylori infection remains a core risk factor, and its pathogenic mechanism is well validated. The bacterium participates in ulcer formation through multiple pathways: damaging the gastric mucosal barrier, promoting inflammatory responses, and affecting gastric acid secretion. Its urease decomposes urea to produce ammonia, directly damaging epithelial cells; the cytotoxin-associated gene protein it releases induces epithelial cell apoptosis; and cytokines released during inflammation activate immune cells, creating a chronic inflammatory environment. H. pylori infection also weakens mucosal defense by affecting gastric mucosal blood flow and reducing mucus secretion. Because H. pylori is closely linked to ulcer recurrence in children, the high infection rate observed here suggests the need to strengthen eradication therapy and follow-up management. The 63.0 percent infection rate in this cohort is comparable to some previous pediatric studies, though regional prevalence, referral patterns, and diagnostic methods can produce variation — one multicenter study in southern Vietnam reported H. pylori positivity in 93.8 percent of children with peptic ulcers.

Lifestyle habits emerged as significant contributors. The proportion of children attending boarding school was 77.2 percent in the ulcer group versus 28.3 percent in controls, and multivariate regression confirmed boarding status as an independent risk factor with an odds ratio of 2.41. The researchers suggest that collective living environments may involve dietary hygiene issues, irregular daily routines, and psychological stress. Boarding children often face a monotonous diet structure and irregular meal times, which may disrupt the rhythm of gastric acid secretion, while differences in hygiene conditions in collective life may increase the risk of H. pylori infection. High-sugar diets, present in 56.5 percent of the ulcer group versus 28.3 percent of controls, participate in ulcer formation by stimulating gastric acid secretion, affecting intestinal flora balance, and promoting inflammatory responses, with an odds ratio of 2.89. Adjusting diet structure may therefore be an effective prevention strategy. Notably, exercise habits and sleep duration showed no significant differences between the two groups.

Family history of digestive system diseases, reported in 30.4 percent of children with ulcers versus 8.7 percent of healthy children, carried an odds ratio of 3.17, indicating that genetic susceptibility plays an important role. Existing research suggests that certain gene polymorphisms — including cytokine genes such as IL-1β and TNF-α — are associated with H. pylori susceptibility, mucosal repair capacity, and the intensity of inflammatory responses, providing molecular biological evidence for the mechanism of genetic factors. This finding aligns with the broader understanding that pediatric peptic ulcer reflects multidimensional interactions among genetic susceptibility, environmental factors, lifestyle habits, and psychosocial influences, rather than any single cause.

Psychological disorders proved to be the strongest independent risk factor, with an odds ratio of 6.11. Prevalence was 63.0 percent in the ulcer group versus 9.8 percent in controls, and the mean SCARED score — from the Screen for Child Anxiety Related Emotional Disorders, with a threshold of 25 or above indicating psychological disorder — was 28.6 ± 8.4 in the ulcer group versus 14.2 ± 6.1 in controls. The researchers invoke the brain-gut axis to explain this connection: psychological disorders such as anxiety and depression activate the hypothalamic-pituitary-adrenal axis and the autonomic nervous system, increasing vagal nerve excitability, gastric acid secretion, and abnormal gastrointestinal motility. Psychological stress can also affect immune regulation, promote inflammatory responses, and alter intestinal flora composition. Importantly, the brain-gut axis operates bidirectionally — chronic pain and reduced quality of life caused by ulcers may further aggravate psychological disorders, forming a vicious cycle that clinicians should address through psychological health assessment and, where necessary, psychological interventions.

The study has limitations that temper interpretation. As a single-center retrospective case-control analysis, it may be subject to selection and information bias; the healthy controls were recruited from children undergoing physical examination at the same hospital rather than from a community-based population, so hospital population bias cannot be completely excluded. Psychological assessment relied on scale scores rather than clinical diagnostic interviews, which may introduce measurement error, and potential confounders such as environmental factors — air pollution, water quality — were not included. Because of the retrospective design, the observed associations should not be interpreted as causal. Nevertheless, the findings provide evidence-based support for early identification and intervention of pediatric peptic ulcer, suggesting that clinical practice should strengthen screening for high-risk children — those with H. pylori infection, high-sugar diets, boarding status, and psychological disorders — and implement comprehensive interventions including eradication therapy, dietary adjustment, and psychological support to improve prognosis. Future multi-center prospective studies with more comprehensive influencing factors and more precise measurement tools are needed to validate the universality and reliability of these conclusions.

Subject of Research: Clinical features and risk factors for pediatric peptic ulcer in children compared with healthy controls

Article Title: Analysis of clinical feature differences and influencing factors between children with peptic ulcer and healthy children

Article References: Chen, C., & Qiu, H. (2026). Analysis of clinical feature differences and influencing factors between children with peptic ulcer and healthy children. Frontiers in Pediatrics, 14, Article 1849123. https://doi.org/10.3389/fped.2026.1849123

Image Credits: AI Generated

DOI: 10.3389/fped.2026.1849123

Keywords: pediatric peptic ulcer, Helicobacter pylori, duodenal bulb, high-sugar diet, boarding school, psychological disorders, brain-gut axis, SCARED, anemia, retrospective study, logistic regression, gastroscopy

The clinical urgency is difficult to overstate. H. pylori infects a large proportion of the global population and is firmly linked to chronic active gastritis, peptic ulcer disease, gastric mucosal atrophy, intestinal metaplasia, and gastric adenocarcinoma. Prospective cohort evidence has connected infection to subsequent gastric cancer development, and meta-analytic data indicate that eradication therapy can reduce cancer risk in appropriate populations. The Kyoto global consensus went so far as to define H. pylori gastritis as an infectious disease that should be diagnosed and treated wherever detected. Yet the therapeutic arsenal is weakening. The Maastricht VI/Florence Consensus Report urges clinicians to tailor regimens to local resistance patterns and prior antibiotic exposure, while the 2024 American College of Gastroenterology guideline now advises against empirical clarithromycin triple therapy unless susceptibility has been confirmed, recommending 14-day optimized bismuth quadruple therapy as the default empirical option when susceptibility is unknown.

Into this resistant landscape, the study’s authors introduce a deliberately small and transparent computational experiment. They selected three targets representing complementary biological functions: H. pylori urease, the nickel-dependent virulence enzyme that allows the bacterium to survive gastric acid by hydrolyzing urea; DNA gyrase subunit A, essential for DNA topology and replication; and shikimate kinase, part of a biosynthetic pathway present in many microorganisms and plants but absent from humans. Crystallographic structures from the Protein Data Bank served for urease (PDB 1E9Y, with its nickel-containing architecture carefully preserved) and shikimate kinase (PDB 1ZUH), while DNA gyrase A was represented by an AlphaFold model because a suitable experimental structure for blind docking was unavailable. Ligands were docked blindly using CB-Dock2, an automated server combining cavity detection with Vina-type scoring, and the resulting poses were inspected in three dimensions and mapped residue-by-residue in two-dimensional diagrams.

The choice of ligands was grounded in prior experimental data rather than computational convenience. Niclosamide, a salicylanilide anthelmintic long used against tapeworms, had already demonstrated striking anti-H. pylori activity in vitro: it inhibited strain 60190 with a minimum inhibitory concentration of 0.25 micrograms per milliliter, remained active at acidic pH, showed partial synergy with metronidazole and proton pump inhibitors, reduced bacterial adhesion and invasion of gastric epithelial cells by roughly 3 log CFU, and produced no detectable resistance after prolonged exposure in a Galleria mellonella infection model. Berberine, a quaternary ammonium alkaloid from plants such as Berberis species, carries clinical credentials of its own. A randomized phase IV trial found that a 14-day quadruple regimen containing berberine achieved eradication rates of 90.1 percent by intention-to-treat and 91.3 percent per protocol, non-inferior to a bismuth-containing regimen, and a later meta-analysis reported that adding berberine to standard triple therapy improved eradication with a risk ratio of 1.22.

The docking results positioned both candidates favorably. Against urease, niclosamide and berberine tied for the most negative score at –8.5 kcal/mol, outperforming levofloxacin’s –7.9 kcal/mol. Berberine again led against DNA gyrase A at –8.5 kcal/mol, ahead of niclosamide at –7.8 and levofloxacin at –7.5 kcal/mol. Shikimate kinase proved the least favorable target overall, with berberine at –7.3, levofloxacin at –7.0, and niclosamide at –6.9 kcal/mol. Across all three targets, berberine posted the most negative descriptive mean score at –8.10 ± 0.69 kcal/mol, compared with –7.73 ± 0.80 for niclosamide and –7.47 ± 0.45 for levofloxacin. The authors are categorical that these Vina-type outputs are ranking scores only, not binding free energies or affinity constants; a favorable docked score can occur even for a compound that fails to bind in solution.

Perhaps the most technically instructive finding emerged from the two-dimensional interaction maps: identical scores can mask entirely different binding modes. At urease, where niclosamide and berberine shared the same –8.5 kcal/mol value, their predicted stabilization patterns diverged sharply. Berberine’s pose relied mainly on pi-alkyl, pi-sigma, and hydrophobic contacts with residues including LEU A:13, ALA A:16, VAL A:33, PHE B:441, and TYR A:32, while niclosamide’s pose combined conventional hydrogen bonds with hydrophobic, pi-related, and van der Waals contacts involving VAL B:473, TYR B:475, PRO B:472, and MET A:12. At DNA gyrase A, berberine’s aromatic contacts with PHE A:549 and TYR A:525 drove its top ranking, whereas levofloxacin interacted with ASP A:91, ARG A:95, and GLN A:98, including one unfavorable positive-positive contact. The authors caution, however, that the isolated DNA gyrase A model cannot reproduce the DNA–enzyme–drug ternary complex on which fluoroquinolone pharmacodynamics actually depends.

The ADMET profiling added a sobering pharmacokinetic dimension. All three compounds showed zero Lipinski rule-of-five violations and identical bioavailability scores of 0.55, with high predicted gastrointestinal absorption, but their developability profiles differ meaningfully. Niclosamide’s consensus logP of 3.78 and topological polar surface area of 49.33 square angstroms predict membrane permeability, yet its poor aqueous solubility makes formulation-oriented work essential. Berberine’s permanent quaternary cationic structure, which was preserved in the docking preparation, is associated with complex, formulation-dependent exposure that demands experimental confirmation. Neither descriptor set, the study emphasizes, constitutes evidence of therapeutic suitability; they flag questions about exposure, solubility, and formulation that only laboratory measurement can resolve.

The methodological self-awareness sets this study apart from much of the computational drug-repurposing literature. The authors explicitly note that no redocking validation, receiver operating characteristic benchmarking, molecular dynamics simulations, or MM/GBSA or MM/PBSA free-energy analyses were performed, meaning pose accuracy and screening enrichment cannot be claimed. Alternative protonation and tautomeric states of the ligands were not systematically enumerated, a constraint that can influence both poses and scores. Thermodynamically, they explain, a docking score approximates none of the free-state, solvation, desolvation, and entropic contributions required for a true binding free energy, and virtual screening workflows carry substantial false-positive rates. With only three ligands and three targets, no inferential statistics were applied; all summaries are purely descriptive of this specific matrix.

The study also situates itself honestly within prior evidence. The docking results neither reproduce niclosamide’s previously observed antibacterial effects nor identify their mechanism; instead they generate a separate, target-oriented hypothesis that urease, gyrase, and shikimate kinase engagement could be tested experimentally. Similarly, the mixed clinical record of berberine—a more recent randomized trial found no clear superiority for berberine-containing triple therapy, and reported MIC values against H. pylori vary widely by strain and method—means the alkaloid should be viewed as a scaffold for mechanistic and formulation-focused testing rather than a docking-supported monotherapy. The shikimate kinase results, with their small score differences, are downgraded to a lower-priority experimental hypothesis despite the target’s theoretical selectivity advantage.

What remains is a deliberately restricted but actionable set of next steps. The authors propose urease inhibition assays as the first priority, followed by broth microdilution or agar-dilution MIC determination against reference and clinical H. pylori strains, checkerboard combination testing with standard antibiotics, cytotoxicity screening on gastric epithelial cell models, and, if justified by results, molecular dynamics and post-docking free-energy analyses. Within this framework, berberine earns the most consistent score pattern, niclosamide remains the clearest repurposing candidate for urease-focused testing given its prior experimental pedigree, and levofloxacin serves its role as a clinically interpretable yardstick. None of these outputs demonstrates binding, enzyme inhibition, bacterial killing, or therapeutic efficacy—but as an exercise in reducing the experimental search space before costly microbiological testing, the study offers a model of how computational prioritization can be conducted with the caveats firmly attached.

Subject of Research: Computational docking and ADMET profiling of niclosamide and berberine against Helicobacter pylori urease, DNA gyrase A, and shikimate kinase

Article Title: Comparative molecular docking and ADMET profiling of niclosamide and berberine against multiple Helicobacter pylori enzymatic targets

Article References: Danila, C., Faur, L., Mocan, L., & Cavalu, D. S. (2026). Comparative molecular docking and ADMET profiling of niclosamide and berberine against multiple Helicobacter pylori enzymatic targets. Pharmacia, 73, Article e212118. https://doi.org/10.3897/pharmacia.73.e212118

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e212118

Keywords: Helicobacter pylori, molecular docking, niclosamide, berberine, levofloxacin, ADMET, drug repurposing, urease, DNA gyrase, shikimate kinase, antimicrobial resistance, in silico screening

The trial, published in Frontiers in Cellular and Infection Microbiology, compared bismuth-containing quadruple therapy built around the new proton pump inhibitor anaprazole against the classical second-generation PPI rabeprazole. Both regimens paired their respective PPI with amoxicillin, furazolidone, and colloidal bismuth pectin, given twice daily for 14 days. A total of 320 treatment-naive patients with confirmed H. pylori infection were enrolled between August 2025 and February 2026 and randomly assigned in a 1:1 ratio. Eradication was assessed by the 13C-urea breath test four weeks after therapy completion, an objective endpoint that is unlikely to be swayed by the open-label design.

The choice of antibiotics was deliberate and rooted in regional resistance data. A 2024 meta-analysis in China reported resistance rates of 70.14 percent for metronidazole, 30.72 percent for clarithromycin, and 32.98 percent for levofloxacin, while resistance to amoxicillin, tetracycline, and furazolidone remained strikingly low at 2.41, 2.53, and 1.54 percent respectively. Surveillance from Nanjing confirmed even more extreme figures, with clarithromycin resistance at 50.01 percent and metronidazole resistance at 84.45 percent, while furazolidone and amoxicillin resistance measured just 0.19 and 0.51 percent. The 2022 Chinese national clinical practice guideline explicitly endorses a bismuth quadruple regimen containing amoxicillin and furazolidone in high-resistance regions such as Jiangsu, making this combination the logical backbone for the trial.

But antibiotics alone do not clear the infection. The degree of acid suppression delivered by the PPI is a critical determinant of success, because raising intragastric pH shifts H. pylori from a dormant state into active replication, rendering it vulnerable to bactericidal agents. Amoxicillin is particularly pH-dependent: when intragastric pH rises from 5.5 to 7.5, its minimum inhibitory concentration against the bacterium drops from 0.5 to 0.06 micrograms per milliliter, dramatically amplifying its killing power. Previous work established that successful eradication with bismuth quadruple therapy requires a median 24-hour intragastric pH of 5.7 or higher. The problem is that conventional PPIs are heavily influenced by CYP2C19 genetic polymorphisms, and rapid metabolizers frequently experience treatment failure due to inadequate acid suppression.

This is where anaprazole’s pharmacology becomes compelling. The novel benzimidazole-class PPI, developed domestically in China and approved by the National Medical Products Administration for duodenal ulcers, features a dihydrofuran ring and a modified pyridine core that reshape its metabolic fate. Clearance is split between non-enzymatic pathways, accounting for 49 percent, and the cytochrome P450 system, accounting for 51 percent. Crucially, CYP3A4 is the dominant enzyme at 48.3 percent of metabolism, while CYP2C19 contributes only 3.5 percent. This profile minimizes the impact of CYP2C19 polymorphisms on acid suppression, promises more consistent interindividual efficacy, and lowers the risk of drug-drug interactions. Radiolabel studies showed total cumulative excretion of 93.20 percent, split between urinary and fecal routes, indicating high absorption and extensive metabolism that may reduce renal burden.

The trial’s non-inferiority design set a prespecified margin of minus 10 percent, a threshold the investigators justified on the grounds that both arms received identical antibiotics and bismuth, leaving the PPI as the only variable. A loss exceeding 10 percent would signal clinically inferior acid suppression, while anything within that margin would preserve the regimen’s utility. Sample size calculations assumed a 90 percent eradication rate for both groups, requiring 142 participants per arm for 80 percent power, with 160 per group enrolled to account for attrition. Randomization used block sizes of four generated by a biostatistician with SAS software, and all centers followed standardized operating procedures with the same medication batches and electronic questionnaires to ensure data consistency.

The results were remarkably tight. In the intention-to-treat analysis, eradication rates were 81.9 percent for anaprazole and 80.0 percent for rabeprazole, a difference of 1.9 percent with a confidence interval spanning minus 6.7 to 10.5 percent. Modified intention-to-treat analysis yielded 89.1 versus 88.9 percent, and per-protocol analysis showed 90.9 versus 90.0 percent. In every analysis set, the lower limit of the 95 percent confidence interval sat comfortably above the minus 10 percent non-inferiority margin, with non-inferiority P values below 0.001. The findings align with earlier phase II and III trials demonstrating anaprazole’s non-inferiority to rabeprazole in duodenal ulcer healing, suggesting its acid-suppressive potency is sufficient to support the intragastric pH target required for eradication, though the study did not directly measure gastric pH.

Safety and adherence data reinforced the picture of equivalence. Adverse events occurred in 22.50 percent of the anaprazole group versus 15.00 percent of the rabeprazole group, a numerical difference that did not reach statistical significance. Specific events including nausea and vomiting, diarrhea, abdominal bloating, rash, constipation, abdominal pain, allergic reactions, and drug fever all showed no significant between-group differences, and no serious adverse events were reported. Medication adherence exceeded 87 percent in both arms, attributed to the simple twice-daily 14-day schedule and stringent guidance. Univariate logistic regression found no significant associations between eradication outcome and sex, age, body mass index, comorbidities, smoking, alcohol use, dining habits, or family history of infection, though a history of other or unknown antibiotic use emerged as a significant risk factor for failure with an odds ratio of 3.874.

The study’s limitations are worth noting. Antimicrobial susceptibility testing was not performed, so primary versus secondary resistance could not be disentangled. The sample size was powered for non-inferiority rather than risk factor analysis, and multivariable modeling was not conducted. All four centers were located in Jiangsu Province, which may limit generalizability across China’s vast and heterogeneous resistance landscape. The open-label design, chosen for operational feasibility, may have introduced information bias in self-reported adverse events, though the objective primary endpoint mitigates this concern. A visual-assisted recall method for antibiotic history, while reducing bias compared with unaided questioning, cannot fully eliminate recall error.

Nevertheless, the trial represents the first randomized clinical evaluation of anaprazole-based quadruple therapy for H. pylori eradication, and its conclusion is clear: the anaprazole-containing regimen is non-inferior to the rabeprazole-based standard across efficacy, safety, and adherence. As antimicrobial resistance continues to erode the effectiveness of first-line antibiotics worldwide, the availability of a PPI with more stable, genotype-independent acid suppression offers a meaningful tool for clinicians. Future studies with double-blind designs, broader geographic coverage, and integrated susceptibility testing will be needed to confirm these findings and refine individualized treatment strategies, but for now, anaprazole has earned a place in the conversation about optimizing H. pylori eradication in the resistance era.

Subject of Research: Anaprazole-based versus rabeprazole-based bismuth quadruple therapy for Helicobacter pylori eradication

Article Title: Anaprazole-based versus rabeprazole-based quadruple therapy for Helicobacter pylori eradication: a prospective, multicenter, randomized controlled trial

Article References: Wang, X., Wang, H., Wang, Y., Shen, L., Li, G., Zhu, J., Li, C., Gao, J., & Zhang, Z. (2026). Anaprazole-based versus rabeprazole-based quadruple therapy for Helicobacter pylori eradication: a prospective, multicenter, randomized controlled trial. Frontiers in Cellular and Infection Microbiology, 16, Article 1972507. https://doi.org/10.3389/fcimb.2026.1972507

Image Credits: AI Generated

DOI: 10.3389/fcimb.2026.1972507

Keywords: Helicobacter pylori, anaprazole, rabeprazole, proton pump inhibitor, bismuth quadruple therapy, antibiotic resistance, furazolidone, amoxicillin, eradication therapy, randomized controlled trial, CYP2C19 polymorphism, gastric cancer

H. pylori is no ordinary stomach dweller. The World Health Organization has classified it as a Group 1 carcinogen since 1994, and colonization of the gastric mucosa by the spiral-shaped, microaerophilic bacterium remains the single major risk factor for gastric cancer. Its persistence hinges on an arsenal of virulence factors, including outer membrane proteins that function as adhesins, molecular grappling hooks that anchor the bacterium to gastric epithelial cells and allow it to resist clearance by mucus turnover, acid flow, and peristalsis. Chief among these adhesins are BabA, which binds Lewis b blood group antigens; SabA, which recognizes sialyl-Lewis X structures; and HopQ, which latches onto members of the CEACAM glycoprotein family. Adhesion is not merely a docking maneuver: successful binding enables the delivery of additional virulence factors such as urease and the cytotoxins CagA and VacA, and it precedes the chronic inflammation that can progress to metaplasia, dysplasia, and carcinoma.

The therapeutic landscape has grown increasingly hostile. Clarithromycin resistance undermined the classic triple therapy of a proton-pump inhibitor plus amoxicillin and clarithromycin, prompting a shift to bismuth-based quadruple regimens built on tetracycline and metronidazole. Yet metronidazole resistance has now been detected at rates that surpass clarithromycin resistance in multiple territories, threatening the fallback regimen as well. Against this backdrop, researchers at the Federal University of Espírito Santo and the Federal University of Santa Catarina in Brazil set out to test whether a standardized silymarin preparation could attack H. pylori on several fronts at once: growth, adhesion, and inflammation.

Silymarin itself is not a single molecule but a mixture of flavonolignans that can constitute up to 70 percent of the crude extract from milk thistle fruits and seeds. The complex is dominated by the enantiomeric pairs silybinin A and B, which together can account for as much as 70 percent of the mixture, alongside isosilybinin A and B, silychristin, isosilychristin, silydianin, and the flavonoid taxifolin. All carry a flavonoid moiety, which underpins the complex’s celebrated antioxidant activity and its long history of use in hepatoprotection, anti-inflammatory, and antifibrotic formulations. Previous work by some of the same team had already shown that silybinin alone inhibits H. pylori, prompting the question of whether the full phytocomplex might perform even better.

The answer, at least in vitro, appears to be yes. Using the broth microdilution method against the reference strain H. pylori ATCC 43504, a strain known to be amoxicillin-susceptible and metronidazole-resistant, the researchers determined a minimum inhibitory concentration of 128 micrograms per milliliter, achieving 90.46 percent growth inhibition. Critically, the minimum bactericidal concentration matched the MIC, meaning the same dose that halted growth also killed the bacteria outright. For comparison, amoxicillin showed an MIC of 0.0625 micrograms per milliliter while metronidazole required 256 micrograms per milliliter against this resistant strain, confirming the expected susceptibility profile.

Scanning electron microscopy then revealed what the treatment does to the bacterium’s architecture. Untreated cells displayed the archetypal helical morphology with smooth surfaces and intact organization. After exposure to half the MIC of silymarin, the bacteria exhibited surface irregularities, cellular deformation, and the emergence of coccoid-like round forms, a pattern consistent with a membrane-targeted mechanism. The changes resembled, though were less extensive than, the severe membrane disruption caused by amoxicillin, which destroys the cell wall. Prior studies suggest silymarin increases membrane permeability, and its flavonolignans have been linked to interference with protein and RNA synthesis as well as disruption of the enzymes bacteria need for energy production.

Safety and selectivity were addressed before any anti-inflammatory claims could be made. In MTT assays, silymarin showed an IC50 of 46.27 micrograms per milliliter against AGS gastric adenocarcinoma cells and 98.18 micrograms per milliliter against RAW 264.7 macrophages, yielding a selectivity index of 2.12, roughly a twofold preference for killing cancer cells over healthy immune cells. Cisplatin, by contrast, showed almost no selectivity between the two cell types. Importantly, at the concentrations used in the immunological experiments, macrophage viability remained above 90 percent, ensuring that the dramatic reductions in inflammatory mediators were genuine pharmacological effects rather than artifacts of cell death.

Those effects were substantial. When macrophages were stimulated with H. pylori and treated with 50 micrograms per milliliter of silymarin, production of tumor necrosis factor-alpha fell by 80.82 percent, interleukin-6 dropped by 76.24 percent, and nitric oxide plummeted by 97.50 percent. Each mediator matters: TNF-alpha activates the NF-kappaB pathway that amplifies the inflammatory cascade and has been implicated in gastric carcinogenesis, while IL-6 drives a feedback loop between macrophages and gastric epithelial cells that promotes cancer, and sustained nitric oxide generates reactive nitrogen species capable of oxidative DNA damage. Notably, the complex outperformed pure silybinin on nitric oxide suppression, 97.50 percent versus 73.33 percent in earlier work, hinting at additive or synergistic contributions from the full flavonolignan mixture.

Adhesion assays added a third dimension to the picture. Using fluorescence-labeled H. pylori and AGS gastric cells, the team found that silymarin inhibited bacterial attachment in a concentration-dependent manner, with the highest tested dose of 256 micrograms per milliliter reducing adhesion by 25.87 percent. That figure is moderate, but it sits within the range reported for other natural anti-adhesive agents, including green tea epigallocatechin gallate, cranberry proanthocyanidins, and garlic-derived organosulfur compounds. Because attachment is the critical first step in colonization, even partial interference could impair the establishment of infection, and blocking adhesin binding sites may also indirectly dampen the expression of virulence factors such as VacA and CagA.

To probe the mechanism, the researchers turned to molecular docking, individually fitting all eight major silymarin constituents into the crystal structures of BabA, SabA, and HopQ. Isosilybinin A scored highest against BabA, forming hydrogen bonds with residues CYS189 and SER244; isosilychristin performed best against SabA, interacting with LYS152 and GLN159; and silychristin led against HopQ through contacts with SER135, ILE130, and ILE242. The results were validated with a consensus docking strategy using AutoDock Vina, since no co-crystallized small-molecule inhibitors exist for these adhesins. Encouragingly, the key residues targeted are highly conserved across H. pylori strains, and their substitution is known to cripple adhesin function. The authors caution that docking was performed on isolated compounds rather than the whole extract, so the computational results support plausible ligand-target interactions but do not fully explain the activity of the intact phytocomplex.

Physicochemical predictions rounded out the evaluation. All eight compounds showed mildly lipophilic logP values between 0.85 and 1.85 with satisfactory aqueous solubility, and all complied with Lipinski’s rule of five, the classical benchmark for oral drug-likeness. That profile is consistent with silymarin’s decades of oral use as a phytotherapeutic agent. Taken together, the study positions the milk thistle complex as a genuinely multifunctional candidate against H. pylori, one that simultaneously curbs bacterial growth, disrupts cellular architecture, suppresses three major inflammatory mediators, and undermines the adhesion machinery the pathogen depends on. The work remains at the in vitro and computational stage, and clinical translation will require further validation, but it offers a compelling case that an ancient herbal remedy may hold modern answers to one of medicine’s most stubborn gastric adversaries.

Subject of Research: Antibacterial, anti-inflammatory, and anti-adhesive effects of silymarin from milk thistle against Helicobacter pylori

Article Title: Effect of silymarin on Helicobacter pylori growth and adhesion: in vitro and in silico evaluation

Article References: Majeski, V. Z., Bittencourt, M. L. F., Tregnago, P. H., Loose, D. N., Federico, L. B., Kitagawa, R. R., & Ribeiro Gonçalves, R. D. C. (2026). Effect of silymarin on Helicobacter pylori growth and adhesion: in vitro and in silico evaluation. Frontiers in Natural Products, 5, Article 1890760. https://doi.org/10.3389/fntpr.2026.1890760

Image Credits: AI Generated

DOI: 10.3389/fntpr.2026.1890760

Keywords: silymarin, Helicobacter pylori, milk thistle, flavonolignans, antibacterial, anti-inflammatory, molecular docking, adhesins, gastric cancer, natural products, antibiotic resistance, Silybum marianum

Graves’ disease is an organ-specific autoimmune disorder in which the immune system generates stimulatory autoantibodies against the thyroid-stimulating hormone receptor. When these antibodies bind the receptor, they activate the adenylate cyclase signaling pathway inside thyroid cells, driving the gland to produce hormone relentlessly. The result is diffuse goiter, hyperthyroidism, and in many patients infiltrative ophthalmopathy, the eye disease that can accompany the condition. The disorder most commonly strikes women between the ages of thirty and sixty, and its incidence has been rising in recent years while the average age of patients has been falling. Current treatments, which include anti-thyroid drugs, radioactive iodine, and thyroidectomy, suffer from low remission rates, high relapse rates, and meaningful complications, which is precisely why researchers are keen to understand the upstream events that set the disease in motion.

The suspicion that infections might be involved is not fringe science. Many infectious agents have been implicated in the onset and progression of noncommunicable diseases, particularly autoimmune conditions, and antibody-mediated immune responses represent the body’s principal defense against pathogenic microorganisms. Patients with Graves’ disease, whose immune systems run persistently hot, might respond differently to certain pathogens than healthy individuals. Some patients, for example, have tested positive for hepatitis C virus antibodies. Observational and mechanistic studies have repeatedly suggested that infectious agents may contribute to autoimmune thyroid disease, but the direction of the relationship, and the immune pathways underneath it, have remained stubbornly uncertain.

This is where Mendelian randomization enters the picture. The method exploits the random assortment of genetic variants at conception as a kind of natural randomized controlled trial. Because variants inherited at conception are fixed for life and largely independent of environmental confounders, they can serve as instrumental variables to test whether an exposure plausibly causes an outcome, or vice versa, without the confounding and reverse causation that plague traditional observational studies. The design rests on three assumptions: the genetic variants must be strongly associated with the exposure, they must be independent of confounders, and they must influence the outcome only through the exposure. When these assumptions hold, the technique offers causal inference at a fraction of the cost and duration of a clinical trial.

The research team, led by investigators affiliated with Shanghai University of Traditional Chinese Medicine and the Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, assembled genetic instruments for forty-six antibody-mediated immune-response phenotypes spanning thirteen pathogens, drawing on a large genome-wide association study within the UK Biobank. These phenotypes included fifteen case-control measures of seropositivity and thirty-one quantitative assessments of antibody levels. Graves’ disease data came from the Finnish FinnGen database, specifically the strict definition encompassing 3,176 cases and 409,005 controls, all of European ancestry. The analysts applied stringent filtering criteria, setting a genome-wide significance threshold of five times ten to the minus eight, pruning variants for linkage disequilibrium, and excluding weak instruments with F-statistics below ten to guard against bias.

In the forward analysis, which asked whether antibody responses cause Graves’ disease, the answer after rigorous multiple-testing correction was a resounding no. None of the forty-six phenotypes was significantly associated with Graves’ disease risk after Bonferroni or false discovery rate correction. Three Epstein-Barr virus antibody phenotypes showed nominal inverse associations under the inverse-variance weighted method, the workhorse estimator of the field, but these signals dissolved under correction. Worse, sensitivity analyses revealed heterogeneity among the genetic variants for all three, and the ZEBRA antibody phenotype additionally showed evidence of horizontal pleiotropy, meaning the variants may influence the disease through pathways other than antibody levels. In plain terms, the tantalizing hints linking viral antibody responses to Graves’ risk do not survive scrutiny.

The reverse analysis told a more interesting story. When the researchers treated genetic liability to Graves’ disease as the exposure and antibody responses as the outcome, several associations survived multiple-testing correction. After jointly weighing correction thresholds, heterogeneity, and pleiotropy, five associations emerged without substantial violations of the instrumental-variable assumptions. Genetic liability to Graves’ disease was associated with lower cytomegalovirus pp52 and pp150 antibody levels, higher Helicobacter pylori UreA antibody levels, higher anti-polyomavirus 2 IgG seropositivity, and higher anti-Merkel cell polyomavirus IgG seropositivity. Of these, only the polyomavirus 2 association remained significant after false discovery rate correction, with an odds ratio of 1.156 and a confidence interval of 1.050 to 1.273, though it did not reach the stricter Bonferroni threshold. The remaining four were nominally significant and must be treated as hypothesis-generating rather than definitive.

Steiger directionality testing added a crucial layer of confidence. Applicable to the thirty-one continuous antibody-level phenotypes, the test evaluates which trait explains more genetic variance in the other. For twenty-nine of the thirty-one phenotypes, the variance explained in Graves’ disease exceeded that explained in the antibody phenotype, and the proposed direction, Graves’ liability influencing antibody levels rather than the reverse, was statistically supported. Among the five prioritized associations, directionality was confirmed for the three continuous antibody-level traits, while the two binary seropositivity phenotypes could not be formally assessed because the required counts of seropositive and seronegative participants were unavailable.

The biological context for these findings is rich. Cytomegalovirus, a ubiquitous DNA virus that lurks in tissues and can reactivate during immune deficiency, has been implicated in other autoimmune conditions, with elevated pp52 antibodies observed in systemic lupus erythematosus and reduced levels seen in multiple sclerosis, mirroring the lower pp52 levels the genetic analysis associated with Graves’ liability. Antibodies against the pp150 protein, which is central to viral maturation and release, have been shown to cross-react with the human CIP2A protein, contributing to the death of CD56-bright natural killer cells, a cell population whose depletion is a shared feature of many autoimmune diseases. Helicobacter pylori, best known for gastritis and gastric cancer, has documented links to autoimmune thyroid disease, and antibodies against the bacterium can cross-react with thyroid tissue, while proteins such as urease may share epitopes with thyroid follicular cells, a textbook setup for molecular mimicry. Polyomaviruses add further intrigue, as Simian virus 40-like sequences have been detected in thyroid tissue from a subset of Graves’ disease patients.

The authors are careful to frame their conclusions at the level of genetically predicted traits rather than established immunological mechanisms, and they acknowledge clear limitations. The analyses relied on European-ancestry data, so generalizability across populations remains uncertain, and the Graves’ disease genetic data came from a single Finnish repository. The antibody phenotypes themselves are proxies for humoral immunity and cannot capture acute pathogen exposure, the timing of infection, viral reactivation, cellular immunity, or local immune events within thyroid tissue. Still, the big picture is striking: the study finds no credible evidence that antibody responses to infections cause Graves’ disease, while lending genetic weight to the idea that Graves’ disease, or the biology underlying it, reshapes the antibody landscape against cytomegalovirus, Helicobacter pylori, and polyomaviruses. If those findings hold up in longitudinal and mechanistic work, the field may need to stop asking which infection triggers Graves’ disease and start asking what the disease does to the immune system’s memory of infection.

Subject of Research: Bidirectional Mendelian randomization analysis of antibody-mediated immune responses to infections and Graves' disease

Article Title: The causal relationship between antibody-mediated immune responses to infections and Graves’ disease: a bi-directional Mendelian randomization analysis

Article References: Zhang, X., Xu, W., Liu, Z., Zhang, J., & Yang, X. (2026). The causal relationship between antibody-mediated immune responses to infections and Graves’ disease: a bi-directional Mendelian randomization analysis. Experimental Biology and Medicine, 251, Article 11238. https://doi.org/10.3389/ebm.2026.11238

Image Credits: AI Generated

DOI: 10.3389/ebm.2026.11238

Keywords: Graves' disease, Mendelian randomization, autoimmune thyroid disease, antibody responses, Epstein-Barr virus, cytomegalovirus, Helicobacter pylori, polyomavirus, genome-wide association study, molecular mimicry, humoral immunity, thyroid autoimmunity

Metronidazole is administered as a prodrug, meaning it enters pathogen cells in an inert form and must be chemically reduced inside the cell before it can inflict damage. This requirement for intracellular activation is not a design flaw but the secret of the drug’s exquisite selectivity. Anaerobic and microaerophilic organisms, which include the amoeba Entamoeba histolytica, the intestinal flagellate Giardia lamblia, the sexually transmitted parasite Trichomonas vaginalis, and the stomach-dwelling bacterium Helicobacter pylori, rely on low-redox-potential fermentation pathways that oxygen-dependent human cells lack. These pathways unwittingly serve as activation machinery, reducing the nitro group of metronidazole to generate short-lived nitro radical anions. Once formed, these radicals transfer electrons to oxygen or to cellular macromolecules, ultimately producing DNA strand breaks, protein damage, and other lesions that trigger catastrophic cell death. The drug, in effect, hijacks the very biochemistry that lets these pathogens survive without oxygen.

The review delineates four major activation pathways, along with an additional route that appears to operate only in Trichomonas. The classical and best-characterized route runs through pyruvate-ferredoxin oxidoreductase, or PFOR, an enzyme central to anaerobic energy metabolism. PFOR passes electrons to low-molecular-weight electron carriers such as ferredoxin, and metronidazole acts as an electron acceptor downstream of these carriers, receiving the electrons that convert it into its cytotoxic radical form. This arrangement explains why disruptions to PFOR expression or to ferredoxin-mediated electron transport so frequently accompany resistance in Entamoeba, Giardia, and Trichomonas. When the electron pipeline that feeds the drug’s activation is throttled back, less of the prodrug is converted into its lethal form, and the parasite gains a survival advantage.

Beyond the classical pathway, the review highlights a family of enzymes known as oxygen-insensitive nitroreductases, or NTRs, which can activate metronidazole independently of the ferredoxin-linked machinery. These nitroreductases reduce the nitro group through a two-electron mechanism that does not require the extremely low oxygen tensions that inhibit other reductive routes. Their existence demonstrates that pathogen cells possess redundant means of arming the drug, a feature that complicates resistance strategies because a parasite must suppress every activation pathway to fully protect itself. Indeed, the review emphasizes that resistant isolates often show layered changes, combining reduced PFOR activity with altered nitroreductase expression and shifts in overall redox metabolism.

Counterbalancing the activators are enzymes that perform the opposite function. Nitroimidazole reductases, known as NIMs, reduce metronidazole in a manner that avoids the formation of the toxic nitro radical, instead converting the compound into non-cytotoxic derivatives. In Entamoeba, the presence or upregulation of such detoxifying activity can dramatically blunt the drug’s effectiveness, contributing directly to resistance phenotypes. The balance between activation enzymes and detoxification enzymes therefore functions as a molecular seesaw: the tipping point determines whether a given dose of metronidazole sterilizes the infection or merely selects for a hardier parasite population. Understanding the genetic and environmental factors that tilt this balance is now a central goal for researchers seeking reliable biomarkers of treatment failure.

Perhaps the most striking recent advance documented in the review is the identification of an alternative activation route involving the malic enzyme. This metabolic enzyme, long appreciated for its role in decarboxylating malate and shuttling reducing equivalents within parasite cells, appears capable of reducing metronidazole and thereby contributing to its activation. The discovery expands the roster of host enzymes that the drug can co-opt and suggests that resistance mechanisms targeting only the classical PFOR-ferredoxin axis may leave this secondary route intact. It also raises intriguing questions about how metabolic flux within the parasite cell, shaped by nutrient availability and environmental conditions, might modulate drug efficacy from one infection context to another.

Equally consequential is the emerging understanding of how activated metronidazole actually kills the parasite. Rather than a nonspecific barrage of radical damage, cell death in Entamoeba histolytica appears to unfold through an organized program. The review’s authors report that metronidazole-associated oxidative stress induces the activation of apoptosis-inducing factor, a mitochondrial-flavoprotein homolog that translocates to the nucleus and fragments DNA in a caspase-independent fashion. In parallel, the drug triggers nucleophagy, an autophagic process directed at the cell’s own nucleus. Together, these two processes contribute decisively to the death of the trophozoite, the feeding and pathogenic stage of the amoeba. The finding reframes metronidazole’s lethality as a form of regulated cell death, opening the possibility that drugs designed to modulate these death pathways could potentiate existing therapy.

Transcriptomic studies of resistant Giardia lines add a genome-wide dimension to the resistance story. Analyses of laboratory-selected resistant parasites reveal coordinated changes in genes governing redox metabolism, oxidative stress responses, and energy metabolism. Rather than a single resistance mutation, resistance in Giardia emerges as a systems-level remodeling of cellular physiology: the parasite recalibrates its electron-handling networks to minimize activation of the prodrug, simultaneously bolstering its defenses against the reactive oxygen species that the activated drug generates, and adjusting its energy metabolism to accommodate the loss of pathways it has downregulated. This polygenic architecture helps explain why resistance in the clinic can be variable, difficult to predict, and dependent on the history of drug exposure in a given parasite population.

In Helicobacter pylori, the bacterium responsible for peptic ulcers and gastric cancer, the resistance landscape looks somewhat different. Here, resistance most frequently arises through mutations in, or complete inactivation of, nitroreductase-encoding genes such as rdxA and frxA. Because these enzymes are required to convert metronidazole into its active form, their loss renders the bacterium effectively blind to the drug. Additional mechanisms, including heightened oxidative stress tolerance and cellular efflux systems that pump the compound back out of the cell, can further reduce susceptibility. The contrast between the parasitic and bacterial strategies underscores a common evolutionary theme: pathogens defeat metronidazole either by refusing to activate it or by surviving and expelling its effects once activated, and both routes are being traversed in parallel across the microbial world.

The review frames these diverse findings as evidence of a continuous co-evolutionary contest between metronidazole and the pathogens it targets, a contest in which each side exploits or subverts the other’s biochemistry. The authors argue that decoding these molecular mechanisms is essential for three practical objectives: improving current therapeutic strategies, identifying new drug targets exposed by the activation and death pathways, and designing next-generation nitroimidazole derivatives or combination therapies that circumvent resistance. If activation by the malic enzyme or the NTRs can be pharmacologically enhanced, or if the apoptosis-inducing factor and nucleophagy response can be therapeutically amplified, existing doses might regain potency against resistant strains. Conversely, screening for NIM activity or rdxA mutations could guide precision prescribing. What remains clear is that metronidazole’s future depends on the continued dissection of the very anaerobic biochemistry that made it a miracle drug in the first place, and that this newly consolidated mechanistic framework offers researchers a detailed map for the battles ahead.

Subject of Research: Mechanisms of metronidazole activation, cytotoxicity, and resistance in anaerobic and microaerophilic pathogens

Article Title: Mechanistic insights into metronidazole activation and antiprotozoal action in anaerobic parasites

Article References: Bandyopadhyay, A., & Ghosh, S. K. (2026). Mechanistic insights into metronidazole activation and antiprotozoal action in anaerobic parasites. Frontiers in Parasitology, 5, Article 1946584. https://doi.org/10.3389/fpara.2026.1946584

Image Credits: AI Generated

DOI: 10.3389/fpara.2026.1946584

Keywords: metronidazole, nitroimidazole, Entamoeba histolytica, Giardia lamblia, Trichomonas vaginalis, Helicobacter pylori, PFOR, ferredoxin, nitroreductase, apoptosis-inducing factor, drug resistance, anaerobic parasites